Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Zevalin Post-marketing Surveillance for Adequateness of Image Interpretation Criteria in Japan (ZEVALIN-SDUI)

This study has been completed.
Information provided by:
Bayer Identifier:
First received: August 11, 2011
Last updated: November 22, 2011
Last verified: November 2011
This study is a regulatory post-marketing surveillance of Zevalin (ibritumomab tiuxetan) in Japan. In-111 Zevalin is, at first, injected to patient for gamma scan imaging to assess biodistribution of the Zevalin. When the imaging shows no altered distribution, Y-90 Zevalin is injected to the patient for the actual treatment. The objective of this study is to assess appropriateness and necessity of revision of the standardized criteria for image interpretation of In-111 Zevalin by comparing assessment by the investigator and the members of the committee for image interpretation of In-111 Zevalin. A total 40 patients will be recruited.

Condition Intervention
Non-Hodgkin's Lymphoma (NHL)
Drug: [111]In-ibritumomab tiuxetan (Zevalin, BAY86-5128)

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Special Drug Use Investigation of Zevalin

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Assessment of abnormal distribution of In-111 Zevalin by the investigator [Two scales; Yes or No] [ Time Frame: At 48-72 hours after In-111 Zevalin injection ]
  • Assessment of abnormal distribution of In-111 Zevalin by the central committee [Two scales; Yes or No] [ Time Frame: At 48-72 hours after In-111 Zevalin injection ]

Enrollment: 72
Study Start Date: August 2008
Study Completion Date: February 2011
Groups/Cohorts Assigned Interventions
Group 1 Drug: [111]In-ibritumomab tiuxetan (Zevalin, BAY86-5128)
Patients who have received In-111 Zevalin.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The target population of this study is 40 patients who received In-111 Zevalin to access biodistribution of Zevalin.

Inclusion Criteria:

  • Patients who received In-111 Zevalin to verify that expected biodistribution is present.

Exclusion Criteria:

  • Patients who are contraindicated based on the product label.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01479387

Many Locations, Japan
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Head Medical Development Japan, Bayer Yakuhin Co.LTD. Identifier: NCT01479387     History of Changes
Other Study ID Numbers: 15043
Study First Received: August 11, 2011
Last Updated: November 22, 2011

Keywords provided by Bayer:
Non-Hodgkin's lymphoma
Mantle cell lymphoma

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs processed this record on May 24, 2017